Dmitry Balyasny’s Genomic Health, Inc. GHDX Stock Holding History

Dmitry Balyasny’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-37,376	Closed	-$2.17M	–	1778
2019 Q2	$2.17M	Buy	37,376 +19,342	+107%	+$1.15M	0.01%	849
2019 Q1	$1.26M	Sell	18,034 -1,187	-6%	-$88K	0.01%	954
2018 Q4	$1.24M	Buy	+19,221	New	+$1.35M	0.01%	840
2017 Q4	–	Sell	-10,000	Closed	-$321K	–	2465
2017 Q3	$321K	Buy	+10,000	New	+$315K	﹤0.01%	1508
2016 Q1	–	Sell	-14,770	Closed	-$520K	–	1635
2015 Q4	$520K	Buy	+14,770	New	+$396K	﹤0.01%	821

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Dmitry Balyasny's GHDX Position: Q3 2019 in Review

Dmitry Balyasny sold out of Genomic Health, Inc. (GHDX) in Q3 2019, closing a stake of 37,376 shares — an estimated $2.17M sold.

Dmitry Balyasny first reported a position in GHDX in Q4 2015 and held it in 5 quarters. The position peaked at $2.17M in Q2 2019. 221 funds tracked by Wall St. Rank hold GHDX as of Q3 2019.

Dmitry Balyasny reported no remaining Genomic Health, Inc. position as of Q3 2019 after selling out during the quarter.
Dmitry Balyasny sold 37,376 Genomic Health, Inc. shares in Q3 2019, an estimated $2.17M.
Dmitry Balyasny first reported a position in Genomic Health, Inc. in Q4 2015 and held it in 5 quarters.
Dmitry Balyasny's Genomic Health, Inc. position peaked at $2.17M in Q2 2019.
221 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q3 2019.

Based on Balyasny Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.